6.22
6.22 (0.22%)
As of Aug 19, 2022
La Jolla Pharmaceutical Co [LJPC]
Source:
Company Overview
We are dedicated to the development and commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases. GIAPREZA(angiotensin II) injection is approved by theU.S. Food and Drug Administration (FDA)as a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock. XERAVA(eravacycline) for injection is approved by the FDA as a tetracycline class antibacterial indicated for the treatment of complicated intra-abdominal infections (cIAI) in patients 18 years of age and older.
| Country | United States |
| Headquarters | waltham, massachusetts |
| Phone Number | 617-715-3600 |
| Industry | manufacturing |
| CEO | La Jolla Pharmaceutical Co |
| Website | ljpc.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $10.5 |
| Operating Profit | $-1.1 |
| Net Income | $2.5 |
| Net Cash | $0 |
Profit Ratios
| Gross Margin | |
| Operating Margin | -10.1 |
| Profit as % of Revenues | |
| Profit as % of Assets | 2,450.7% |
| Profit as % of Stockholder Equity | -3,538.3% |
Management Effectiveness
| Return on Equity | -24.5% |
| Return on Assets | 17.1% |
| Turnover Ratio | 105.1% |
| EBITA |
Balance Sheet and Cash Flow Measures
| Total Assets | $99.4 |
| Total Liabilities | $168.8 |
| Operating Cash Flow | $0 |
| Investing Cash Flow | $0 |
| Financing Cash Flow | $0 |
